Oncology – Gastrointestinal
#ADA2022 – Retrospective Cohort Study: Association of bariatric surgery with cancer risk and mortality in adults with obesity.
6 Jun, 2022 | 11:54h | UTCAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (free for a limited period)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (free for a limited period)
News Release: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Commentaries on Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
#ASCO22 – Phase 2 single-arm study: PD-1 Blockade in mismatch repair–deficient, locally advanced rectal cancer.
6 Jun, 2022 | 11:12h | UTCPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Consensus Statement: Current role of immunotherapy in gastric, esophageal and gastro-esophageal junction cancers.
3 Jun, 2022 | 11:24h | UTC
Review: Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis.
3 Jun, 2022 | 10:51h | UTC
M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.
3 Jun, 2022 | 10:46h | UTC
RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
2 Jun, 2022 | 10:49h | UTCDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Commentary on Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022
Retrospective Cohort Study: Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer.
1 Jun, 2022 | 11:17h | UTC
Update on perioperative management of patients undergoing surgery for liver cancer.
1 Jun, 2022 | 11:11h | UTC
Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: A meta-analysis beyond 10 years of follow-up.
31 May, 2022 | 11:47h | UTC
Commentary from the author on Twitter (thread – click for more)
Our latest research letter is published in @AGA_Gastrohttps://t.co/MCJBLgwh1F
It was inspired by two recent long-term follow-ups of RCTs of population screening and treatment for H. pylori to prevent gastric cancer published in the journal.
— Alexander Ford (@alex_ford12399) May 20, 2022
RCT: Rivaroxaban vs. placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.
31 May, 2022 | 11:19h | UTC
Current guidelines in the surgical management of hereditary colorectal cancers.
27 May, 2022 | 12:00h | UTC
Cohort Study: Age at initiation of lower gastrointestinal endoscopy and colorectal cancer risk.
27 May, 2022 | 11:26h | UTCAge at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women – JAMA Oncology (link to abstract – $ for full-text)
Commentaries:
Related:
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
ACG Clinical Guidelines: Colorectal Cancer Screening 2021 – The American Journal of Gastroenterology
Screening and prevention of colorectal cancer – The BMJ
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
Initiation of an endoscopy before age 50 was associated with lower risk of colorectal cancer incidence & young-onset cancer. These findings support recent guidelines that recommend initiating colorectal cancer screening before age 50. https://t.co/T85cIS5AIS #CRCSM #GICSM
— JAMA Oncology (@JAMAOnc) May 5, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Observational study suggests hepatic arterial infusion pump chemotherapy may be an alternative to resection for patients with multifocal intrahepatic cholangiocarcinoma.
23 May, 2022 | 00:52h | UTCComparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma – JAMA Surgery (link to abstract – $ for full-text)
Commentaries:
Treating iCCA With Chemo Pump Can Be as Effective as Surgery, JAMA Study Finds – AJMC
Commentaries on Twitter
This study found that resection of multifocal intrahepatic cholangiocarcinoma should be carefully considered. Hepatic artery infusion pump chemotherapy may be an effective treatment option. https://t.co/lp1KwSCJvi
— JAMA Surgery (@JAMASurgery) May 12, 2022
In this cohort study of 319 patients with multifocal intrahepatic cholangiocarcinoma, those treated with HAIP floxuridine chemotherapy had similar overall survival to those who underwent resection. @FlavioRochaMD @michael_lidsky @JAMASurgery @HopSTranCao @sepideh_gholami https://t.co/P7O3B7JLRo
— Syed A. Ahmad (@SyedAAhmad5) May 18, 2022
Review | Esophageal adenocarcinoma: A dire need for early detection and treatment.
19 May, 2022 | 10:24h | UTC
The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study.
19 May, 2022 | 10:19h | UTC
[News release – not published yet] Gallstone disease shown to be a strong predictor of pancreatic cancer.
16 May, 2022 | 01:49h | UTC
Guideline for Pancreatic Cancer: A summary of evidence-based surgical approaches.
12 May, 2022 | 10:09h | UTC
M-A: Chemoradiotherapy followed by active surveillance vs. standard esophagectomy for esophageal cancer.
12 May, 2022 | 07:51h | UTCChemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Guideline: Endoscopic submucosal dissection for superficial gastrointestinal lesions.
10 May, 2022 | 10:53h | UTC
RCT: Final analysis of 3 vs. 6 months of adjuvant Oxaliplatin and Fluoropyrimidine-based therapy in patients with Stage III colon cancer.
10 May, 2022 | 10:40h | UTC
Commentaries on Twitter
In Asian (Japan) patients with stage III colon cancer, 3 months of CAPOX therapy is an appropriate adjuvant treatment option in patients with low-risk disease- ACHIEVE trialhttps://t.co/BzjepOoal8
— K Pavithran (@drkpavithran) May 6, 2022
M-A: Comparison of survival among adults with rectal cancer who have undergone laparoscopic vs. open surgery.
10 May, 2022 | 10:43h | UTC
Commentary on Twitter
This meta-analysis of 12 RCTs found laparoscopic rectal cancer resection is associated with better long-term overall survival vs open surgery, suggesting it may be time for routine use of laparoscopic surgery for rectal cancer. https://t.co/jb7YAkHDWM
— JAMA Network Open (@JAMANetworkOpen) May 9, 2022
Current and future colorectal cancer screening strategies.
10 May, 2022 | 10:34h | UTCCurrent and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
M-A: Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment.
3 May, 2022 | 10:33h | UTC
RCT: Tislelizumab vs. chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
3 May, 2022 | 10:36h | UTC
Commentary on Twitter
In the phase III RATIONALE-302 trial of tislelizumab vs chemotherapy as 2nd-line therapy for advanced-stage ESCC, mOS was 8.6 vs 6.3 months (HR 0.70; P=0.0001), rising to 10.3 vs 6.8 months for those with a PD-L1 tumour area positivity score >10%: https://t.co/CNxads2Kn2 #esocsm
— NatureRevClinOncol (@NatRevClinOncol) April 27, 2022